arlevertan 20 mg - 40 mg tabl.
hennig arzneimittel gmbh & co. kg - dimenhydrinate 40 mg; cinnarizine 20 mg - tablet - 20 mg - 40 mg - cinnarizine 20 mg; dimenhydrinate 40 mg - cinnarizine, combinations
revertor solution
modern veterinary therapeutics llc - atipamezole hydrochloride - solution - 5mg - atipamezole hydrochloride 5mg - dogs
revertor 5 mg/ml inj. sol. i.m. vial
cp-pharma handelsgesellschaft gmbh - atipamezole hydrochloride 5 mg/ml - eq. atipamezole 4,27 mg/ml - solution for injection - 5 mg/ml - atipamezole hydrochloride 5 mg/ml - atipamezole - dog; cat
reverted reverse transcriptase
africa biosystems tanzania ltd, tanzania - reverse transcriptase kit -
frame, spectacle
australian eyewear distributors pty ltd - 32816 - frame, spectacle - retail and wholesale sale of spectacle frames
amiodarone hydrochloride- amiodarone hydrochloride tablet
cardinal health - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with its use (see warnings below), amiodarone hydrochloride tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. because of the life-threatening nature of
perjeta
roche pharmaceuticals (israel) ltd - pertuzumab - concentrate for solution for infusion - pertuzumab 420 mg / 14 ml - pertuzumab - pertuzumab - early breast cancer perjeta is indicated for use in combination with trastuzumab and chemotherapy for: • the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. • the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence .metastatic breast cancerperjeta is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.
talon xt pro rodenticide wax blocks
syngenta australia pty ltd - brodifacoum - bait - brodifacoum coumarin active 0.05 g/kg - vertebrate poison - agricultural/farm buildings | commercial building/structure - external | commercial building/structure-internal | domestic build - control of rodent resistant to warfarin | mouse - mus domesticus | rat | rat - brown or norway | rodent resitant to bromadiolone | rodents resistant to coumatetralyl
talon rat & mouse killer all weather wax blocks
syngenta australia pty ltd - brodifacoum - bait - brodifacoum coumarin active 0.05 g/kg - vertebrate poison - agricultural/farm buildings | commercial area - general | domestic pest control | industrial land or area | public service area - black rat | brown rat | mouse - mus spp. | rodent, rat or mouse | black rat/mouse | brown rat/mouse | mouse | rat | rodent | roof rat
talon rat & mouse killer pellets
syngenta australia pty ltd - brodifacoum - bait - brodifacoum coumarin active 0.05 g/kg - vertebrate poison - agricultural/farm buildings | industrial and/or domestic premises | animal housing | in and around | premises - mouse - mus spp. | rat